Magnetic resonance imaging in diagnosis and disease monitoring of multiple sclerosis;Stellenwert der magnetresonanztomographie bei diagnose und krankheitsmonitoring der multiplen sklerose

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 151, Issue 2, 2000, Pages 47-56

  Freitag, P ^a   Kappos, L ^b   Radu E W ^a,b  

^a Neuroradiologische Abteilung   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 0034117887     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2000.01144     Document Type: Review

References (78)

1. Grossman RI, McGowan JC. Perspectives on multiple sclerosis. AJNR Am J Neuroradiol 1998;19:1251-65.
2. Miller DH, Grossman RI, Reingold A, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
3. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999;12:337-44.
4. Gass A, Radü EW, Filippi M, Kappos L. MRT-Verlaufsuntersuchungen bei multipler Sklerose. Ein Leitfaden für die Qualitätssicherung. Fortschr Röntgenstr 1999;170:581-6.
5. van Waesberghe JHTM, van Walderveen MAA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-83.
6. van Walderveen MAA, Kamphorst W, Scheltens PH, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-8.
7. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
8. Truyen L, van Waesberghe JHTM, van Walderveen MAA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-76.
9. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990;113:1477-89.
10. Barkhof F, Scheltens P, Frequin STMF, et al. Relapsing remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-7.
11. Silver N, Good CD, MacManus DG, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effect of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149-61.
12. van Waesberghe JHTM, Castelijns JA, Roser W, et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997;18:1279-85.
13. Thompson AJ, Kermode AG, MacManus DG, et al. Major differences in the dynamics of primary and secondary multiple sclerosis. Ann Neurol 1991;29:53-62.
14. Miki Y, Grossman RI, Udupa JK, et al. Computer-assisted quantitation of enhancing lesions in multiple sclerosis: correlation with clinical classification. AJNR Am J Neuroradiol 1997;18:705-10.
15. Miki Y, Grossman RI, Udupa JK, et al. Isolated U-fiber involvement in MS. Preliminary observations. Neurology 1998;50:1301-6.
16. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weigthed brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-60.
17. Thorpe JW, Halpin SF, MacManus DG, et al. A comparison between fast and conventional spin-echo in detection of multiple sclerosis lesions. Neuroradiology 1994;36:388-92.
18. Yousry TA, Filippi M, Becker C, et al. Comparison of MR pulse sequences in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997;18:959-63.
19. Bastianello S, Bozzao A, Paolillo A, et al. Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997;18:699-704.
20. Rovaris M, Gawne-Cain ML, Wang L, et al. A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. Neuroradiology 1997;39:161-5.
21. Bastianello S, Bozzao A, Paolillo A, et al. Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997;18:699-704.
22. Filippi M, Yousry T, Baratti C, et al. Quantitative assessment of MRI lesion load in multiple sclerosis: a comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain 1996;119:1349-55.
23. Miller DH, Kesselring J, Thompson AJ, et al. Magnetic Resonance Imaging in Multiple Sclerosis. Cambridge: Cambridge University Press; 1997.
24. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709-14.
25. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Medicine 1965;122:552-68.
26. Kappos L, Radü EW. Magnetische Resonanztomographie bei Multipler Sklerose: Eine Bestandsaufnahme. Klin Neuroradiol 1991;2:110-26.
27. Fazekas F. Magnetic resonance signal abnormalities in asymptomatic individuals: their incidental and functional correlates. Eur Neurol 1989;29:164-8.
28. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69.
29. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495-503.
30. Kappos L, Moeri D, Radü EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-9.
31. Hittmair K, Mallek R, Prayer D, et al. Spinal cord lesions in patients with multiple sclerosis: comparison of MR pulse sequences. AJNR Am J Neuroradiol 1996;17:1555-65.
32. Lycklama à Nijeholt GJ, Barkhof F, Scheltens P, et al. MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. AJNR Am J Neuroradiol 1997;18:1041-8.
33. Gass A, Fillipi M. Rodegher ME, et al. Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord and optic nerve on T1-weighted MRI. Neurology 1998;50:548-50.
34. Lycklama à Nijeholt GJ, van Walderveen MAA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlations between MRI parameters, clinical subtypes and symptoms. Brain 1998;121:687-97.
35. Lycklama à Nijeholt GJ, Castelijns JA, Weerts J, et al. Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. AJNR Am J Neuroradiol 1998;19:355-60.
36. Dousset V, Gayou A, Brochet B, Caille JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 1998;51:1150-5.
37. Silver N, Lai HM, Symms MR, et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998;51:758-64.
38. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289-93.
39. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-14.
40. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin echo images and non-enhanced T1-weighted images. AJNR Am J Neuroradiol 1995;16:69-77.
41. van Buchem MA, McGowan JC, Kolson DL, et al. Quantitative volumetric magnetisation transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632-6.
42. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999;52:588-94.
43. van Buchem MA, Grossman M, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 1998;50:1609-17.
44. Hiehle JF, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med 1994;32:285-93.
45. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-42.
46. Grossman RI, Lenkinski RE, Ramer KN, et al. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1535-43.
47. Arnold DL, Matthews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-41.
48. Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71.
49. Roser W, Hagberg G, Mader I, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic chances in normal appearing white matter. Magn Reson Med 1995;33:811-7.
50. Fu L, Matthews PM, De Stephano N, et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998;121:103-13.
51. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. Brain 1995;118:1583-92.
52. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive method with potential to monitor disease progression. Brain 1996;119:701-8.
53. Stevenson VL, Leary SM, Losseff N, et al. Spinal cord atrophy and disability in MS. A longitudinal study. Neurology 1998;51:234-8.
54. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119:2009-19.
55. Simon JH, Jacobs LD, Campion M, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-48.
56. Barkhof F, Elton M, Lindeboom J, et al. Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. J Neurol 1998;245:153-8.
57. Berry I, Ranjeva J-P, Duthil P, et al. Ultrafast magnetic resonance imaging of the brain and spine. In: Debatin JF, McKinnon GC. Ultrafast MRI. Techniques and applications. Berlin: Springer; 1998. p. 53-97.
58. Clanet M, Berry I, Boulanouar K. Functional imaging in multiple sclerosis. The International MS Journal 1997;4:27-32.
59. Rombouts SARB, Lazeron, RHC, Scheltens P, et al. Visual activation patterns in patients with optic neuritis: an fMRI pilot study. Neurology 1998;50:1896-9.
60. Horsfield M, Larsson HBW, Jones DK, Gass A. Diffusion magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998:64(S):80-4.
61. Werring DJ, Clark CA, Barker GJ, et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999;52:1626-32.
62. Horsfield MA, Lai D, Webb S, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 1996;36:393-400.
63. Francis DA, Compston DAS, Barchelor JR, McDonald WI. A reassessment of the risk of developing multiple sclerosis in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987;50:758-65.
64. Gass A, Barker GJ, MacManus D, et al. High resolution magnetic resonance imaging of the anterior visual pathway in patients with optic neuropathies using fast spin echo phased array local coils. J Neurol Neurosurg Psychiatry 1995;58:562-9.
65. Davies MB, Williams R, Haq N, et al. MRI of the optic nerve and postchiasmal visual pathways and visual evoked potentials in secondary progressive multiple sclerosis. Neuroradiology 1998;40:765-70.
66. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
67. Barkhof F, Filippi M, Miller DH, et al. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84.
68. Paty DW, Li DKB, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
69. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon ss-1a for relapsing multiple sclerosis. Ann Neurol 1993;43:79-87.
70. Li DKB, Paty DW, et al. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
71. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
72. Corni G, Filippi M, and the Copaxone MRI Study Group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Neurology 1999;52(S2):289.
73. Guttmann CR, Ahn SS, Hsu L, et al. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995;16:1481-91.
74. Gerig G, Welti D, Guttmann C, et al. Exploring the discrimination power of the time domain for segmentation and characterisation of lesions in serial MR data. In: Wells W, Colchester A, Delp S. Medical Image Computing and Computer-assisted Intervention. MICCAI 1998. p. 469-80.
75. Lee MA, Smith S, Palace J, Matthews PM. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 1998;121:2095-102.
76. Paty DW, Oger JJF, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study of comparison with clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988;38:180-5.
77. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-5.
78. Barkhof F, Filippi M, Horsfield MA, et al. Towards specific magnetic resonance imaging criteria in the early diagnosis of multiple sclerosis. Neurology 1995;45(S4):398.